Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Non-Current Deffered Revenue (2018 - 2025)

10x Genomics (TXG) has disclosed Non-Current Deffered Revenue for 6 consecutive years, with $10.5 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deffered Revenue fell 16.08% to $10.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.5 million through Dec 2025, down 16.08% year-over-year, with the annual reading at $10.5 million for FY2025, 16.08% down from the prior year.
  • Non-Current Deffered Revenue hit $10.5 million in Q4 2025 for 10x Genomics, down from $10.9 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $12.6 million in Q1 2025 to a low of $3.2 million in Q4 2022.
  • Historically, Non-Current Deffered Revenue has averaged $10.3 million across 4 years, with a median of $11.1 million in 2025.
  • Biggest five-year swings in Non-Current Deffered Revenue: surged 178.48% in 2023 and later decreased 16.08% in 2025.
  • Year by year, Non-Current Deffered Revenue stood at $3.2 million in 2022, then soared by 178.48% to $8.8 million in 2023, then skyrocketed by 41.97% to $12.5 million in 2024, then fell by 16.08% to $10.5 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for TXG at $10.5 million in Q4 2025, $10.9 million in Q3 2025, and $11.3 million in Q2 2025.